Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors
Pleasanton, CA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases. We are pleased to announce the appointment of one new independent board member, Michael Friedman, MBA as a Class III Director and as a member of the Company’s Audit Committee and Compensation Committee.
“Our Board of Directors is comprised of an experienced and dedicated team of biotech leaders committed to advancing our portfolio of clinical-stage assets and preclinical platform programs. We are excited to channel Michael’s talent, breadth of experience, expertise, and energy into furthering our mission and continue to strengthen our Board.” Stephen LaMond, Interim CEO, COO & Hoyoung Huh, MD, PhD., Founder and Director.
Mr. Friedman served as Senior Vice President at Ladenburg Thalmann & Co. Inc. Healthcare Investment Banking where he focused on M&A and capital markets from 2017 to 2023. Mr. Friedman has worked with numerous biotech, pharmaceutical and healthcare services companies for over 15 years and has executed a significant number of M&A, IPO, leveraged finance, and equity follow-on transactions. Previously, Michael was an investment banker for Bank of America Merrill Lynch, Jefferies and Baird. He holds an MBA from the University of Chicago; Booth School of Business and he received his BBA from the University of Wisconsin. The Company’s Board of Directors believes Mr. Friedman’s significant experience advising biopharmaceutical companies in M&A and finance qualifies him to serve on our board of directors.
About Peak Bio, Inc.
Peak Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases. Peak Bio’s lead product candidate, PHP-303, is a 5th generation, small molecule, neutrophil elastase inhibitor currently awaiting initiation of a Phase II clinical study in the genetic orphan disease called Alpha1 anti-trypsin deficiency disorder (AATD). Peak Bio has successfully completed two Phase 1 clinical studies in human subjects: a single ascending dose trial (SAD) and a multiple ascending dose trial (MAD). The SAD and MAD PHP-303 clinical studies demonstrated a favorable safety profile, and a dose was established for Peak Bio’s upcoming clinical trials. Peak Bio’s cancer platform consists of novel payloads/toxins in conjunction an antibody-drug conjugate (ADC) platform that seeks to address a growing unmet need in cancer care. Peak Bio’s current ADC approach has a dual mechanism of action that seeks to unit conventional and direct targeting of cancer cells with toxins while also engaging the immune system with the added potential to enhance cancer cell killing. The Peak Bio payload seeks to stimulate the immune system by leaving behind immune memory cells that continue to kill cancer cells following the initial therapeutic intervention even in the absence of further ADC treatments. The potential for immune reengagement when the cancer reoccurs could be an exciting and important advancement in cancer care with this dual mechanistic approach to cancer therapeutics. Peak Bio’s lead payload appears to be a poor substrate for multi-drug resistance (MDR) transporters which is a growing concern in the ADC field.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Forward-looking statements generally can be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continues,” “could,” “estimates,” “expects,” “goal,” “intends,” “may,” “on track,” “opportunity,” “plans,” “poised for,” “possible,” “potential,” “predicts,” “projects,” “promises to be,” “seeks,” “should,” “target,” “will,” “would” or similar expressions and the negatives of those terms.Although we believe that our plans, intentions, expectations, strategies, and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; preclinical testing or early clinical results may not be predictive of the results or success of ongoing or later preclinical or clinical studies; identification, development and testing of the company’s product candidates and new platforms may take longer and/or cost more than planned, or our clinical studies may not be initiated or completed on schedule; risks inherent in drug development in general; difficulties enrolling patients in our clinical trials; failure to realize any value of our product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission (“SEC”), including our most recently filed Registration Statement on Form S-1 filed with the SEC and our most recently filed Annual Report on Form 10-K filed with the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.
Contact:
Stephen LaMond, PharmD, MBA
Interim CEO and COO
Peak Bio, Inc.
steve.lamond@peak-bio.com
